Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
Homerun Resources Inc. Files for Approval of $3 Million Financing; Updates $6 Million Institutional Financing
